Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16621 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Jingmin Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Glucagon-Like Peptides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk (Shanghai) Pharma Trading Co., Ltd.
Abstract (Originalsprache)
Aims
Cardiorenal effects of semaglutide in people with type 2 diabetes (T2D) at high cardiovascular (CV) risk were investigated. Materials and Methods Post hoc analyses of pooled SUSTAIN 6 (NCT01720446) and PIONEER 6 (NCT02692716) data assessed time to primary major adverse CV events (MACE; CV death, non‐fatal myocardial infarction, or non‐fatal stroke), expanded MACE (MACE + hospitalisation for unstable angina or heart failure), CV death, all‐cause death, and new or worsening nephropathy. The impact of body weight (BW) changes on primary MACE risk was also evaluated. Participants were stratified by prior CV disease (CVD) status and baseline body mass index (BMI).
Results
Semaglutide significantly reduced the risk of primary and expanded MACE, with a nonsignificant risk reduction of CV and all‐cause death versus placebo in the overall population; the effect was consistent across all subgroups ( p INT >0.05 for all comparisons). Semaglutide consistently reduced nephropathy risk versus placebo in the SUSTAIN 6 population (HR [95% CI]: 0.64 [0.46; 0.88], p = 0.0054) and across all subgroups ( p INT >0.05 for all comparisons). When accounting for BW changes, treatment effects on primary MACE risk in the overall population and by BMI subgroups remained similar compared with the results of the main analysis.
Conclusions
Semaglutide treatment improved cardiorenal outcomes versus placebo in people with T2D, regardless of prior CVD and baseline BMI. This improvement was observed even when accounting for changes in BW, indicating direct effects of semaglutide on the cardiorenal system. This analysis supports the broad efficacy of semaglutide in a diverse T2D population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Ted Rogers Centre for Heart Research, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Novo Nordisk (Shanghai) Pharma Trading Co., Ltd, Beijing, China.
- Clinical Research, Steno Diabetes Center Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Jingmin Zhou, Mansoor Husain
Förderung
- Novo Nordisk (Shanghai) Pharma Trading Co., Ltd
Zitieren
APA
Zhou, J., Husain, M., Li, Y., Liu, W., Shen, Z., Vilsbøll, T., & Ge, J. (2025). Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16621
Vancouver
Zhou J, Husain M, Li Y, Liu W, Shen Z, Vilsbøll T, et al. Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16621
BibTeX
@article{Zhou2025,
author = {Zhou, Jingmin and Husain, Mansoor and Li, Yang and Liu, Wenyan and Shen, Zewei and Vilsbøll, Tina and Ge, Junbo},
title = {Effect of semaglutide versus placebo on cardiorenal outcomes by prior cardiovascular disease and baseline body mass index: Pooled post hoc analysis of SUSTAIN 6 and PIONEER 6},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16621}
}
EUVIMED